Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma

This study has been terminated.
(Study terminated.24 subjects enrolled;provided adequate data for decision making.)
Information provided by (Responsible Party):
GlaxoSmithKline ( Sirtris, a GSK Company ) Identifier:
First received: June 12, 2009
Last updated: March 29, 2012
Last verified: March 2012
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: November 2010
  Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):